Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients
BACKGROUND: Relapse after achieving virologic response to anti-hepatitis C virus (HCV) treatment considerably reduces sustained virologic response rates. It is unclear what the main predictors of relapse in HCV/HIV-coinfected patients are.
PATIENTS AND METHODS: The Pegasys Ribavirina España Coinfección (PRESCO) study evaluated short and extended duration of treatment for chronic hepatitis C using pegylated interferon (peg-IFN)-alpha2a at a dose of 180 microg/wk plus weight-based ribavirin (RBV) at a dose of 1000 to 1200 mg/d in HIV-infected subjects. Patients with HCV-2/3 were treated for 6 or 12 months, and patients with HCV-1/4 were treated for 12 or 18 months.
RESULTS: Of 389 patients included in the trial, end-of-treatment response was achieved by 262 (67.3%): 106 with HCV-1 (55%), 137 with HCV-2/3 (90%), and 19 with HCV-4 (41%). Six patients were lost to follow-up after completing therapy. Of the remaining 256 patients, 62 (24%) relapsed: 33% of HCV-1 patients, 18% of HCV-2/3 patients, and 21% of HCV-4 patients. In multivariate logistic regression analysis, baseline serum HCV RNA level > or =500,000 IU/mL (relative risk [RR] = 4.81, 95% confidence interval [CI]: 1.52 to 15.22; P = 0.008) and lack of rapid virologic response, defined as undetectable HCV RNA level at week 4 (RR = 2.94, 95% CI: 1.22 to 7.09; P = 0.02) were the best independent predictors of HCV relapse. Use of concomitant antiretroviral therapy also predicted relapse (P = 0.04), and a trend toward a higher relapse rate was recognized for HCV genotypes 1 and 4 versus genotypes 2 and 3 (P = 0.08). Extended treatment did not result in a lower incidence of relapse, at least for HCV genotypes 2 and 3.
CONCLUSION: High baseline serum HCV RNA level and lack of undetectable viremia at week 4 are the most significant predictors of relapse in HCV/HIV-coinfected patients treated with peg-IFN plus weight-based RBV.
Errataetall: | |
---|---|
Medienart: |
Artikel |
Erscheinungsjahr: |
2007 |
---|---|
Erschienen: |
2007 |
Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
---|---|
Enthalten in: |
Journal of acquired immune deficiency syndromes (1999) - 45(2007), 4 vom: 01. Aug., Seite 439-44 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Núñez, Marina [VerfasserIn] |
---|
Anmerkungen: |
Date Completed 27.08.2007 Date Revised 30.09.2020 published: Print ErratumIn: J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):528 Mariño, Angel [corrected to Mariño, Ana] Citation Status MEDLINE |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
NLM169984435 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM169984435 | ||
003 | DE-627 | ||
005 | 20231223122524.0 | ||
007 | tu | ||
008 | 231223s2007 xx ||||| 00| ||eng c | ||
028 | 5 | 2 | |a pubmed24n0567.xml |
035 | |a (DE-627)NLM169984435 | ||
035 | |a (NLM)17468669 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Núñez, Marina |e verfasserin |4 aut | |
245 | 1 | 0 | |a Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients |
264 | 1 | |c 2007 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a Date Completed 27.08.2007 | ||
500 | |a Date Revised 30.09.2020 | ||
500 | |a published: Print | ||
500 | |a ErratumIn: J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):528 Mariño, Angel [corrected to Mariño, Ana] | ||
500 | |a Citation Status MEDLINE | ||
520 | |a BACKGROUND: Relapse after achieving virologic response to anti-hepatitis C virus (HCV) treatment considerably reduces sustained virologic response rates. It is unclear what the main predictors of relapse in HCV/HIV-coinfected patients are | ||
520 | |a PATIENTS AND METHODS: The Pegasys Ribavirina España Coinfección (PRESCO) study evaluated short and extended duration of treatment for chronic hepatitis C using pegylated interferon (peg-IFN)-alpha2a at a dose of 180 microg/wk plus weight-based ribavirin (RBV) at a dose of 1000 to 1200 mg/d in HIV-infected subjects. Patients with HCV-2/3 were treated for 6 or 12 months, and patients with HCV-1/4 were treated for 12 or 18 months | ||
520 | |a RESULTS: Of 389 patients included in the trial, end-of-treatment response was achieved by 262 (67.3%): 106 with HCV-1 (55%), 137 with HCV-2/3 (90%), and 19 with HCV-4 (41%). Six patients were lost to follow-up after completing therapy. Of the remaining 256 patients, 62 (24%) relapsed: 33% of HCV-1 patients, 18% of HCV-2/3 patients, and 21% of HCV-4 patients. In multivariate logistic regression analysis, baseline serum HCV RNA level > or =500,000 IU/mL (relative risk [RR] = 4.81, 95% confidence interval [CI]: 1.52 to 15.22; P = 0.008) and lack of rapid virologic response, defined as undetectable HCV RNA level at week 4 (RR = 2.94, 95% CI: 1.22 to 7.09; P = 0.02) were the best independent predictors of HCV relapse. Use of concomitant antiretroviral therapy also predicted relapse (P = 0.04), and a trend toward a higher relapse rate was recognized for HCV genotypes 1 and 4 versus genotypes 2 and 3 (P = 0.08). Extended treatment did not result in a lower incidence of relapse, at least for HCV genotypes 2 and 3 | ||
520 | |a CONCLUSION: High baseline serum HCV RNA level and lack of undetectable viremia at week 4 are the most significant predictors of relapse in HCV/HIV-coinfected patients treated with peg-IFN plus weight-based RBV | ||
650 | 4 | |a Clinical Trial | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Multicenter Study | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Antiviral Agents |2 NLM | |
650 | 7 | |a Interferon alpha-2 |2 NLM | |
650 | 7 | |a Interferon-alpha |2 NLM | |
650 | 7 | |a RNA, Viral |2 NLM | |
650 | 7 | |a Recombinant Proteins |2 NLM | |
650 | 7 | |a Polyethylene Glycols |2 NLM | |
650 | 7 | |a 3WJQ0SDW1A |2 NLM | |
650 | 7 | |a Ribavirin |2 NLM | |
650 | 7 | |a 49717AWG6K |2 NLM | |
650 | 7 | |a peginterferon alfa-2a |2 NLM | |
650 | 7 | |a Q46947FE7K |2 NLM | |
700 | 1 | |a Mariño, Ana |e verfasserin |4 aut | |
700 | 1 | |a Mariño, Angel |e verfasserin |4 aut | |
700 | 1 | |a Miralles, Celia |e verfasserin |4 aut | |
700 | 1 | |a Berdún, Miguel A |e verfasserin |4 aut | |
700 | 1 | |a Sola, Julio |e verfasserin |4 aut | |
700 | 1 | |a Hernandez-Burruezo, Juan Jose |e verfasserin |4 aut | |
700 | 1 | |a Galindo, Maria Jose |e verfasserin |4 aut | |
700 | 1 | |a Barreiro, Pablo |e verfasserin |4 aut | |
700 | 1 | |a Martin-Carbonero, Luz |e verfasserin |4 aut | |
700 | 1 | |a Soriano, Vincent |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of acquired immune deficiency syndromes (1999) |d 1999 |g 45(2007), 4 vom: 01. Aug., Seite 439-44 |w (DE-627)NLM101679912 |x 1944-7884 |7 nnns |
773 | 1 | 8 | |g volume:45 |g year:2007 |g number:4 |g day:01 |g month:08 |g pages:439-44 |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 45 |j 2007 |e 4 |b 01 |c 08 |h 439-44 |